Apr 1, 20211 min
$CYDN +18% New protocol discussed with FDA, specifically to duplicate or surpass the 82% survival rate over placebo. source
$GILD +3% Submits BLA for Tecartus. source
$KDMN +2% Ph 2 initiated. source
$RLMD +4% Initiates ph 3 study of REL-1017. source
$PASG -3% Ph 1/2 study initiated. source
$UTHR +15% FDA approval of Tyvaso for PH-ILD. source